US 2021/0171589 A1Published application

Truncated cartilage-homing peptides and peptide complexes and methods of use thereof

AssigneeBlaze Bioscience, Inc.

InventorsNatalie Winblade NAIRN, Scott PRESNELL, Claudia JOCHHEIM, Mark STROUD

Life of this patent

Estimating the term…

Loading patent…

Abstract

Truncated, variant, or mutated peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for truncated or mutated peptides or truncated or mutated peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver truncated or mutated peptide or truncated, variant, or mutated peptides or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.

Claims174

Dependent claims

A peptide comprising:

a) any one of SEQ ID NO:
87, SEQ ID NO:
88, SEQ ID NO:
107, SEQ ID NO:
108, SEQ ID NO:
219, SEQ ID NO:
223, SEQ ID NO:
225, or a functional fragment thereof, or
b) any one of SEQ ID NO:
89, SEQ ID NO:
106, and SEQ ID NO:
221, or a functional fragment thereof and further comprising at least one amino acid in each of SEQ ID NO:
89, SEQ ID NO:
106, and SEQ ID NO:
221 is selected from the group consisting of:
i) for SEQ ID NO:
89, wherein X1 is selected from N, S, or G, wherein X2 is selected from L or Y, wherein X3 is selected from D or E, wherein X4 is selected from M or T, wherein X5 is selected from N, Q, A, S, T, or L, wherein X6 is selected from S, G, or R, wherein X7 is selected from H or Y, and wherein X8 is selected from T or Y;
ii) for SEQ ID NO:
106, wherein X1 is selected from L or Y, wherein X2 is selected from D or E, wherein X3 is selected from M or T, wherein X4 is selected from N, Q, A, S, T, or L, wherein X5 is selected from S, G, or R, wherein X6 is selected from H or Y, and wherein X7 is selected from T or Y;
iii) for SEQ ID NO:
221, wherein each X and X1-13 are individually any amino acid or no amino acid and at least one of the following residues at the denoted position, more than one of the following residues at the denoted position, or all of the following residues at the denoted position is included in SEQ ID NO:
221:
X1 is K, X2 is Q, X3 is Y, X4 is E, X5 is K, X6 is T, X7 is K, X8 is M, X9 is Q, A, S, T, or L, X10 is G, X11 is K, X12 is Y, or X13 is Y;
iv) a corresponding substitution selected from the group consisting of N5S, D16E, M23T, N30Q, N30A, N30S, N30T, N30L, S31G, S31R, L15Y, H34Y, T36Y, D10E, M17T, N24Q, N24A, N24S, N24T, N24L, S25G, S25R, L9Y, H28Y, T30Y, R1K, R13K, R14K, R21K, and R26K.

21 more elements

A peptide, wherein

a) the peptide comprises a sequence that has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, or at least 100% sequence identity with any one of SEQ ID NO:
109, SEQ ID NO:
110, SEQ ID NO:
260, or SEQ ID NO:
262 and wherein the peptide further comprises a joining sequence of one or more amino acid residues located immediately adjacent to an N-terminus or a C-terminus of the peptide and wherein
i) N−1 is selected from the group consisting of G, A, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
ii) N−2 is selected from the group consisting of G, A, V, L, I, M, F, W, P, S, T, C, Y, Q, D, E, K, R, and H;
iii) N−3 is selected from the group consisting of G, A, V, L, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
iv) N−4 is selected from the group consisting of G, A, V, L, I, M, F, W, S, T, C, Y, N, Q, D, E, K, R, and H;
v) N−5 is selected from the group consisting of G, A, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
or
vi) N−6 is selected from the group consisting of A, V, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H
b) the peptide comprises a sequence that has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, or at least 100% sequence identity with SEQ ID NO:
129 and wherein the peptide further comprises a joining sequence of one or more amino acid residues located immediately adjacent to an N-terminus or a C-terminus of the peptide and wherein N−1 is selected from the group consisting of A, V, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
c) the peptide comprises a sequence that has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, or at least 100% sequence identity with SEQ ID NO:
130 and wherein the peptide further comprises a joining sequence of one or more amino acid residues located immediately adjacent to an N-terminus or a C-terminus of the peptide and wherein
i) N−1 is selected from the group consisting of G, A, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
or
ii) N−2 is selected from the group consisting of A, V, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
d) the peptide comprises a sequence that has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, or at least 100% sequence identity with SEQ ID NO:
131 and wherein the peptide further comprises a joining sequence of one or more amino acid residues located immediately adjacent to an N-terminus or a C-terminus of the peptide and wherein
i) N−1 is selected from the group consisting of G, A, V, L, I, M, F, W, S, T, C, Y, N, Q, D, E, K, R, and H;
ii) N−2 is selected from the group consisting of G, A, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
or
iii) N−3 is selected from the group consisting of A, V, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
e) the peptide comprises a sequence that has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, or at least 100% sequence identity with SEQ ID NO:
132 and wherein the peptide further comprises a joining sequence of one or more amino acid residues located immediately adjacent to an N-terminus or a C-terminus of the peptide and wherein
i) N−1 is selected from the group consisting of G, A, V, L, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
ii) N−2 is selected from the group consisting of G, A, V, L, I, M, F, W, S, T, C, Y, N, Q, D, E, K, R, and H;
iii) N−3 is selected from the group consisting of G, A, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
or
iv) N−4 is selected from the group consisting of A, V, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
f) the peptide comprises a sequence that has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, or at least 100% sequence identity with SEQ ID NO:
133 and wherein the peptide further comprises a joining sequence of one or more amino acid residues located immediately adjacent to an N-terminus or a C-terminus of the peptide and wherein
i) N−1 is selected from the group consisting of G, A, V, L, I, M, F, W, P, S, T, C, Y, Q, D, E, K, R, and H;
ii) N−2 is selected from the group consisting of G, A, V, L, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
iii) N−3 is selected from the group consisting of G, A, V, L, I, M, F, W, S, T, C, Y, N, Q, D, E, K, R, and H;
iv) N−4 is selected from the group consisting of G, A, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
v) N−5 is selected from the group consisting of A, V, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, and H;
g) the peptide comprises a sequence that has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, or at least 100% sequence identity with SEQ ID NO:
260 and wherein the peptide further comprises a joining sequence of one or more amino acid residues located immediately adjacent to an N-terminus or a C-terminus of the peptide and wherein
i) C+1 is selected from the group consisting of G, A, V, L, I, M, F, W, P, S, C, Y, N, Q, D, E, K, R, and H;
or
ii) C+2 is selected from the group consisting of G, A, V, L, I, M, F, W, S, T, C, Y, N, Q, D, E, K, R, and H;
or
h) the peptide comprises a sequence that has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, or at least 100% sequence identity with SEQ ID NO:
262 and wherein the peptide further comprises a joining sequence of one or more amino acid residues located immediately adjacent to an N-terminus or a C-terminus of the peptide and wherein C+1 is selected from the group consisting of G, A, V, L, I, M, F, W, S, T, C, Y, N, Q, D, E, K, R, and H.

44 more elements

A peptide comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99%, or 100% sequence identity with any one of SEQ ID NO:

209-SEQ ID NO:
215, wherein the peptide further comprises an active agent and wherein the active agent is complexed with the peptide to form a peptide active agent complex.

Dependencies are inferred from the claim text.

Facts

Application: 16/980,787Filed 15 Mar 2019
Priority: 16 Mar 2018
Published: 10 Jun 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 14/47
From vertebrates: from mammals
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 47/64
The modifying agent being a protein, peptide or polyamino acid: drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying…
A61K 47/65
The modifying agent being a protein, peptide or polyamino acid: peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Family

Application62/644,329Us provisional application · filed 16 Mar 2018
Application62/676,033Us provisional application · filed 24 May 2018
US 2021/0171589 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key